Peter R. Carroll

Song H, Xu J, Velazquez-Arcelay K, Demirci A, Raizenne BL, Hsu SC, Choi J, Pham JH, Chen YA, Weinstein HNW, Salzman I, Tsui M, Akutagawa J, Adingo W, Goldschmidt E, Carroll PR, Hong JC, Heaphy CM, Cooperberg MR, Greenland N, Campbell JD, Huang FW. A single-cell and spatial atlas of prostate cancer r

Shee K, Pace WA, Song JJ, Raizenne BL, Cowan JE, Wang L, Washington SL, Shinohara K, Nguyen HG, Carroll PR, Cooperberg MR. A High Decipher Genomic Risk Score Is Associated with Major Pathological Progression in Patients Undergoing Active Surveillance for Prostate Cancer. Eur Urol Oncol. 2026 Jan 30.

Pace WA, Olshen A, Wang Y, Kenfield SA, Van Blarigan EL, Graff RE, Cowan J, Wang L, Tenggara I, Lopez K, Encabo K, Jones LW, Panchal N, Cooperberg MR, Carroll PR, Luke A, Pollak M, Chan JM. Inflammation and insulin profiles in men assigned to exercise vs. usual care for prostate cancer: results from

Odisho AY, Liu AW, Pace WA, Carlisle MN, Krumm R, Cowan JE, Carroll PR, Cooperberg MR. Generative Artificial Intelligence Successfully Automates Data Extraction From Unstructured Magnetic Resonance Imaging Reports: Feasibility in Prostate Cancer Care. JCO Clin Cancer Inform. 2026 Jan; 10:e2400334.

Carlisle MN, Pace WA, Liu AW, Krumm R, Cowan JE, Carroll PR, Cooperberg MR, Odisho AY. Development and Validation of a Generative Artificial Intelligence-Based Pipeline for Automated Clinical Data Extraction From Electronic Health Records: Technical Implementation Study. JMIR Bioinform Biotechnol. 2

McKenney JK, Brooks JD, Nguyen JK, Ding CKC, Newcomb LF, Myles JL, Alaghehbandan R, Przybycin CG, Chan E, Simko JP, Greenland NY, Schwen Z, Weight CJ, Cooperberg MR, Carroll PR. In reply to: 'Prostate cancer with favorable histology is not synonymous with prostate cancer indolence'. Histopathology.

Li KD, Carlisle MN, Jarosek S, Patel HV, Faris A, Elliott SP, Cooperberg MR, Carroll PR, Breyer BN. Evolving Risk of Urinary Adverse Events Across Localized Prostate Cancer Treatments: A Propensity-weighted Analysis of Surveillance, Epidemiology and End Results-Medicare Data. Eur Urol. 2026 Jan; 89(

Shee K, Cowan JE, Ding CC, Wang L, Pace W, Greenland N, Simko JP, Washington SL, Shinohara K, Nguyen HG, Cooperberg MR, Carroll PR. Gleason Grade Group 3 Represents a Spectrum of Disease: Results from a Large Institutional Cohort. Eur Urol Focus. 2026 Jan; 12(1):61-69.

Evolving Risk of Urinary Adverse Events Across Localized Prostate Cancer Treatments: A Propensity-weighted Analysis of Surveillance, Epidemiology and End Results-Medicare Data

Liu L, Lian L, Hao Y, Pace A, Kim E, Homsi N, Pershad Y, Lai L, Gracie T, Kishtagari A, Carroll PR, Bick AG, Odisho AY, Chung M, Yala A. Human level information extraction from clinical reports with finetuned language models. Sci Rep. 2025 Nov 24; 15(1):45239.

Chen WS, Tuchayi AM, Sabbagh A, Kim I, Porter E, Ashraf-Ganjouei A, Li YR, Witztum A, Rajagopal A, Seyedin SN, Juarez R, Carroll PR, Feng FY, Small EJ, Hope TA, Hong JC. Utility of metastasis-directed radiotherapy with and without hormonal therapy in management of oligometastatic prostate cancer. JN

Raizenne BL, Shee K, Cowan JE, Carroll PR, Cooperberg MR. Clinical Comparison of Decipher 1.0 and 1.1 for Localized Prostate Cancer: Results in Prostatectomy and Active Surveillance Patients. Eur Urol Oncol. 2025 Oct; 8(5):1221-1226.

Shee K, Pace WA, Liu AW, Cowan JE, Subramanyam V, Agapito C, Washington SL, Cooperberg MR, Carroll PR, Shinohara K, Nguyen HG. Determining Optimal Patient Selection for High-intensity Focused Ultrasound for Prostate Cancer. Eur Urol Focus. 2025 Nov; 11(6):869-875.

Shee K, Song JJ, Cowan JE, Wang L, Nie J, Chappidi M, Washington SL, Nguyen HG, Cooperberg MR, Shinohara K, Carroll PR. The Natural History of Confirmed Grade Group 1 Prostate Cancer Managed with Active Surveillance in the Modern Era. Eur Urol Oncol. 2025 Aug; 8(4):1094-1100.

Palmer NR, Carroll PR, Washington SL. Time is on our side - rethinking the concept of time to treatment for prostate cancer. Nat Rev Urol. 2025 May; 22(5):251-252.

Chappidi MR, Newcomb LF, Zheng Y, Liu M, Schenk JM, Zhu K, de la Calle CM, Brooks JD, Carroll PR, Dash A, Filson CP, Gleave ME, Liss MA, Martin F, McKenney JK, Morgan TM, Wagner AA, Nelson PS, Lin DW. Magnetic Resonance Imaging at Second Surveillance Biopsy After Diagnosis in Patients With Grade Gro

Kuzuoglu-Ozturk D, Nguyen HG, Xue L, Figueredo E, Subramanyam V, Liu I, Bonitto K, Noronha A, Dabrowska A, Cowan JE, Oses-Prieto JA, Burlingame AL, Worland ST, Carroll PR, Ruggero D. Small-molecule RNA therapeutics to target prostate cancer. Cancer Cell. 2025 May 12; 43(5):841-855.e8.

Fakunle MO, Cowan JE, Washington SL, Shinohara K, Nguyen HG, Carroll PR. Targeted Biopsy Is Sufficient for Men on Active Surveillance for Early-Stage Prostate Cancer. J Urol. 2025 01; 213(1):34-39.

Long-Term Outcomes in Patients Using Protocol-Directed Active Surveillance for Prostate Cancer

Carroll PR. Legends in Urology v31I05. Can J Urol. 2024 Oct; 31(5):11974-11976.

Patient and physician perspectives on treatments for low-risk prostate cancer: a qualitative study

Bicycle Trauma Injuries and Hospital Admissions in the United States, 1998-2013

Prevalence and Impact of Fall-Risk-Increasing Drugs, Polypharmacy, and Drug–Drug Interactions in Robust Versus Frail Hospitalised Falls Patients: A Prospective Cohort Study

The impact of frailty on pharmacokinetics in older people: using gentamicin population pharmacokinetic modeling to investigate changes in renal drug clearance by glomerular filtration

2005-present American College of Radiology’s Appropriateness Criteria Expert Panel on Radiation Oncology-Prostate, AUA representative

2001-present American College of Surgeons Commission on Cancer, AUA representative